133 related articles for article (PubMed ID: 18220505)
1. NMR structural studies of oligosaccharides related to cancer processes.
Jiménez-Barbero J; Díaz MD; Nieto PM
Anticancer Agents Med Chem; 2008 Jan; 8(1):52-63. PubMed ID: 18220505
[TBL] [Abstract][Full Text] [Related]
2. Active conformations of glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with antithrombin and fibroblast growth factors in solution.
Hricovíni M; Guerrini M; Bisio A; Torri G; Naggi A; Casu B
Semin Thromb Hemost; 2002 Aug; 28(4):325-34. PubMed ID: 12244479
[TBL] [Abstract][Full Text] [Related]
3. Conformational flexibility of a synthetic glycosylaminoglycan bound to a fibroblast growth factor. FGF-1 recognizes both the (1)C(4) and (2)S(O) conformations of a bioactive heparin-like hexasaccharide.
Canales A; Angulo J; Ojeda R; Bruix M; Fayos R; Lozano R; Giménez-Gallego G; Martín-Lomas M; Nieto PM; Jiménez-Barbero J
J Am Chem Soc; 2005 Apr; 127(16):5778-9. PubMed ID: 15839662
[TBL] [Abstract][Full Text] [Related]
4. Solution NMR characterization of chemokine CXCL8/IL-8 monomer and dimer binding to glycosaminoglycans: structural plasticity mediates differential binding interactions.
Joseph PR; Mosier PD; Desai UR; Rajarathnam K
Biochem J; 2015 Nov; 472(1):121-33. PubMed ID: 26371375
[TBL] [Abstract][Full Text] [Related]
5. Structural aspects of carbohydrates and the relation with their biological properties.
Hricovíni M
Curr Med Chem; 2004 Oct; 11(19):2565-83. PubMed ID: 15544464
[TBL] [Abstract][Full Text] [Related]
6. Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue.
Canales A; Lozano R; López-Méndez B; Angulo J; Ojeda R; Nieto PM; Martín-Lomas M; Giménez-Gallego G; Jiménez-Barbero J
FEBS J; 2006 Oct; 273(20):4716-27. PubMed ID: 16995857
[TBL] [Abstract][Full Text] [Related]
7. Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy.
Guglier S; Hricovíni M; Raman R; Polito L; Torri G; Casu B; Sasisekharan R; Guerrini M
Biochemistry; 2008 Dec; 47(52):13862-9. PubMed ID: 19117094
[TBL] [Abstract][Full Text] [Related]
8. Properly oriented heparin-decasaccharide-induced dimers are the biologically active form of basic fibroblast growth factor.
Moy FJ; Safran M; Seddon AP; Kitchen D; Böhlen P; Aviezer D; Yayon A; Powers R
Biochemistry; 1997 Apr; 36(16):4782-91. PubMed ID: 9125499
[TBL] [Abstract][Full Text] [Related]
9. Interaction of heparins with fibroblast growth factors: conformational aspects.
Guerrini M; Hricovíni M; Torri G
Curr Pharm Des; 2007; 13(20):2045-56. PubMed ID: 17627538
[TBL] [Abstract][Full Text] [Related]
10. Diversity does make a difference: fibroblast growth factor-heparin interactions.
Faham S; Linhardt RJ; Rees DC
Curr Opin Struct Biol; 1998 Oct; 8(5):578-86. PubMed ID: 9818261
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of human acidic fibroblast growth factor and interaction with heparin-derived hexasaccharide.
Ogura K; Nagata K; Hatanaka H; Habuchi H; Kimata K; Tate S; Ravera MW; Jaye M; Schlessinger J; Inagaki F
J Biomol NMR; 1999 Jan; 13(1):11-24. PubMed ID: 10070748
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional structures of oligosaccharides.
Woods RJ
Curr Opin Struct Biol; 1995 Oct; 5(5):591-8. PubMed ID: 8574693
[TBL] [Abstract][Full Text] [Related]
13. Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding.
Wang H; Toida T; Kim YS; Capila I; Hileman RE; Bernfield M; Linhardt RJ
Biochem Biophys Res Commun; 1997 Jun; 235(2):369-73. PubMed ID: 9199199
[TBL] [Abstract][Full Text] [Related]
14. The promise of glycomics, glycan arrays and carbohydrate-based vaccines.
Lepenies B; Seeberger PH
Immunopharmacol Immunotoxicol; 2010 Jun; 32(2):196-207. PubMed ID: 20141495
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin-binding oligosaccharides: structural diversities in a unique function?
Guerrini M; Mourier PA; Torri G; Viskov C
Glycoconj J; 2014 Oct; 31(6-7):409-16. PubMed ID: 25145542
[TBL] [Abstract][Full Text] [Related]
16. Direct measurement of the interactions of glycosaminoglycans and a heparin decasaccharide with the malaria circumsporozoite protein.
Rathore D; McCutchan TF; Garboczi DN; Toida T; Hernáiz MJ; LeBrun LA; Lang SC; Linhardt RJ
Biochemistry; 2001 Sep; 40(38):11518-24. PubMed ID: 11560500
[TBL] [Abstract][Full Text] [Related]
17. Conformational selection of the AGA*IA(M) heparin pentasaccharide when bound to the fibroblast growth factor receptor.
Nieto L; Canales Á; Giménez-Gallego G; Nieto PM; Jiménez-Barbero J
Chemistry; 2011 Sep; 17(40):11204-9. PubMed ID: 21922554
[TBL] [Abstract][Full Text] [Related]
18. Dynamic properties of biologically active synthetic heparin-like hexasaccharides.
Angulo J; Hricovíni M; Gairi M; Guerrini M; de Paz JL; Ojeda R; Martín-Lomas M; Nieto PM
Glycobiology; 2005 Oct; 15(10):1008-15. PubMed ID: 15958415
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements in heparin for binding and activation of FGF-1 and FGF-4 are different from that for FGF-2.
Ishihara M
Glycobiology; 1994 Dec; 4(6):817-24. PubMed ID: 7537556
[TBL] [Abstract][Full Text] [Related]
20. MALDI mass spectrometry as a tool for characterizing glycosaminoglycan oligosaccharides and their interaction with proteins.
Sturiale L; Naggi A; Torri G
Semin Thromb Hemost; 2001 Oct; 27(5):465-72. PubMed ID: 11668415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
